AFG3L2 and colorectal carcinoma: In the nucleus, CRABP2 promotes CRC progression by interacting with and inhibiting RB1, whereas in the cytoplasm, CRABP2 suppresses CRLM by interacting with the m‐AAA domain of AFG3L2, thereby blocking PINK1 degradation and maintaining mitophagy.